MMS Holdings, Inc.

CANTON, Mich. (August 3, 2023) – TrialAssure, a leading software-as-a-service (SaaS) provider advancing clinical trial disclosure, data sharing, and transparency, announced today that it is collaborating with MMS, a global clinical research organization, on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development. The primary focus of this collaboration is to utilize AI to generate text specifically tailored for creating plain language summary (PLS) documents. These documents help clinical researchers effectively communicate their findings with patients, families, and the public by presenting the results in a manner that is easily understandable to the average reader. “TrialAssure is the perfect partner in this space. Their AI knowledge and their AI-enabled software will allow us to co-create a solution that doesn’t exist in the market today - a tool that generates plain language summaries or other clinical documents automatically,” said Teresa Cesena, Ph.D., Sr. Director of Regulatory & Medical Writing, MMS. “We have been at the forefront of medical writing in the pharmaceutical industry for more than 15 years, and this kind of solution, tailored specifically for the unique needs of highly regulated medical writing documents, will allow us to continue that leadership path and bring fresh solutions to clinical trial sponsors across the globe.” A 2023 Forbes Advisor survey revealed that 64 percent of businesses expect their productivity to increase with artificial intelligence. Increase medical writing efficiency and improve quality This initiative will allow the companies to complete an initial draft of a medical writing document more efficiently. Instead of writing sections from scratch, TrialAssure Link will produce the first draft for the medical writer to review and update. In other words, it will: Reduce the amount of time it takes to produce the first draft Enhance quality, by automatically and appropriately incorporating all the necessary information from source documentation Improve compliance, by introducing reliable and speedy automation “Our AI solutions experts and SMEs with extensive experience in medical writing and clinical trial-related documents are working together hand-in-hand to develop this new technology that will help shape the future of the pharmaceutical industry,” said Zach Weingarden, Director of Product Solutions, TrialAssure. “The possibilities of AI in this industry are endless, and we are exploring additional use cases that target different aspects of the clinical trial and related documents at various stages.” For more information or to see a demo of AI capabilities, visit About MMS MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating. For more information, visit About TrialAssure TrialAssure is a leading, global clinical trial disclosure and data transparency provider with unmatched experience in helping navigate complex regulatory compliance challenges. TrialAssure provides fast, affordable, and intelligent software and service solutions to facilitate clinical trial disclosure (registration and results reporting), document and data anonymization, and enhanced patient engagement, while delivering the highest quality clinical trial transparency deliverables that exceed the most stringent requirements. Established in 2009, TrialAssure regularly adapts to ever-changing clinical trial disclosure and data transparency requirements and was named Data Solution of the Year – Healthcare in the Data Breakthrough Awards. For more information, visit Media Contacts MMS: Prasad Babu, Director-Marketing Operations, pbabu@mmsholdings.com TrialAssure: Don F. McLean, CMO, dmclean@trialassure.com ###

CANTON, Mich.--( BUSINESS WIRE )--MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in different therapeutic areas. “We are pleased to welcome Dr. Breitfeld and Dr. Zeiher to our Scientific Advisory Board,” said Uma Sharma, Ph.D., CEO of MMS. “At MMS, we work with our sponsors to support the development of groundbreaking therapies and bring them to market. Both Bernie and Phil bring much experience in different therapeutic areas and advanced drug development to guide our sponsors and teams with their expertise for many upcoming challenges.” Dr. Breitfeld has nearly 20 years of experience in the pharmaceutical industry and has led development and project teams focusing on Phase 1, Proof of Concept, and Pivotal trials in oncology. He has pharmaceutical development experience in solid tumor and malignant hematology, including leading oncology development at small biotechs and midsized global pharma companies. Prior to MMS, Dr. Breitfeld developed and led the Oncology Center of Excellence at IQVIA, the matrix organization that drives the long-term business agenda for oncology at the organization. “I’m excited to draw from my years of oncology experience to help MMS provide solutions for Sponsors and patients,” said Dr. Breitfeld. “I’m joining a well-respected team of advisors and looking forward to working with them at such an innovative organization.” Dr. Zeiher has led the development of products in critical care, pain, immunology and infectious diseases. He was involved in and oversaw the approval of over 15 products. Over the course of his 20 years in the industry, he has held leadership and executive responsibility positions at Astellas, Pfizer and Lilly, including board memberships, Chief Medical Officer and President of Development. “MMS does great work bringing life-changing therapies to patients,” said Dr. Zeiher. “I’m passionate about addressing patients’ unmet needs, and I’m excited to work for an organization where I can use my years of experience to fulfill that goal.” Both join a team of industry-leading advisors at MMS. Learn more here. About MMS MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.

CANTON, Mich.--( BUSINESS WIRE )--MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer and Ashu Tandon as Chief Commercial Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates, and a Great Place to Work in India. Both Schoonmaker and Tandon have decades of experience in the pharmaceutical and healthcare industry and have held leadership positions at other CROs. “We are excited to welcome Chris and Ashu to the #OneMMS team,” said Dr. Uma Sharma, Chief Executive Officer, MMS. “I look forward to their leadership and strength for our continued growth as we scale our teams and clients globally to be the best in business.” MMS Growth The expansion of the MMS executive leadership team, including the newly created position of Chief Commercial Officer, will allow the company to continue growing its teams and services across its global operations. “I’m excited to join and help expand MMS’ reach as we continue to bring value to Sponsors by helping them bring new therapies to market,” said Tandon, CCO, MMS. “We have strong expertise across our many services, and I look forward to connecting Sponsors with the MMS services that are the right fit for their needs.” Enhancing the MMS Mission MMS has maintained one of the highest retention rates in the pharma industry and a positive colleague culture since its inception. These aspects of MMS enhance its mission of delivering high-quality service and technology solutions to assist clients in developing life-changing therapies. Recently, MMS was recognized for its great company culture by the Top Workplaces USA awards for the second consecutive year. The winners of this award are chosen based solely on employee feedback gathered through an employee engagement survey. “I’m grateful to work at a company with such a strong company culture that cares about its colleagues,” said Schoonmaker, COO, MMS. “Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.” About MMS MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.